

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by postal voting in accordance with Section 3 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

Submitted to Hansa Biopharma AB (publ) no later than June 16, 2020.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Hansa Biopharma AB (publ), Reg. No. 556734-5359 at the Annual General Meeting on June 23, 2020. The voting right is exercised in accordance with the below marked voting options.

Name of the shareholder	Personal identity number/registration number
Telephone number	E-mail
Place and date	
Signature	
Clarification of signature	

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form in original to Advokatfirman Vinge KB, Att: Stephanie Stiernstedt, Box 1703, 111 87 Stockholm. A completed and signed form may also be submitted electronically and shall, in that case, be sent to hansabiopharma@vinge.se.
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. The same applies if the shareholder votes in advance by proxy
- Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting

If a shareholder does not intend to exercise its voting right by way of advance voting, the form for advance voting should not be submitted.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be provided to Hansa Biopharma no later than June 16, 2020. An advance vote can be withdrawn up to and including June 16, 2020 by contacting hansabiopharma@vinge.se. Thereafter, an advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the general meeting.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Hansa Biopharma's webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual General Meeting in Hansa Biopharma on June 23, 2020

The options below comprise the proposals submitted by the Board of Directors and the Nomination Committee which are included in the notice convening the Annual General Meeting.

2. Election of chairman of the meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination as to whether the meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
9(a) Resolution regarding the adoption of the income statement and the balance sheet, and of the consolidated income statement and the consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
9(b) Resolution regarding allocation of the company's result according to the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c) Resolution regarding discharge from liability for the members of the Board of Directors and the CEO
9(c)(i) Ulf Wiinberg, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c)(ii) Birgit Stattin Norinder, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c)(iii) Anders Gersel Pedersen, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c)(iv) Andreas Eggert, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c)(v) Eva Nilsagård, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c)(vi) Mats Blom, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9(c)(vii) Søren Tulstrup, CEO Yes <input type="checkbox"/> No <input type="checkbox"/>
10(a) Determination of the number of members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
10(b) Determination of the number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
11(a) Determination of fees for members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>

<p>11(b) Determination of fees for auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12. Election of the members of the Board of Directors</p>
<p>12(a) Ulf Wiinberg</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12(b) Birgit Stattin Norinder</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12(c) Anders Gersel Pedersen</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12(d) Andreas Eggert</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12(e) Eva Nilsagård</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12(f) Mats Blom</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>13. Election of the chairman of the Board of Directors Ulf Wiinberg</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14. Election of auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>15. Proposal regarding principles for appointing the Nomination Committee</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16. Proposal regarding guidelines for executive remuneration</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17. Proposal regarding the amendment of the articles of association</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18. Proposal to adopt a long-term incentive program based on performance-based share rights for employees at Hansa Biopharma</p>
<p>18(a) Proposal to adopt a long-term incentive program based on performance-based share rights for employees at Hansa Biopharma</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18(b)(i)-(iii) Authorisation for the Board of Directors to issue new class C shares, authorisation to repurchase issued class C shares, transfer own ordinary shares to participants in the programme and the market</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18(c) Equity swap arrangements with third parties</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>

19. Proposal to adopt a long-term incentive program based on employee stock options for employees in Hansa Biopharma

19(a) Proposal to adopt a long-term incentive program based on employee stock options for employees in Hansa Biopharma

Yes No

19(b) Proposal regarding issue and transfer of warrants

Yes No

19(c) Equity swap arrangements with third parties

Yes No

20. Proposal regarding resolution on authorization for the Board of Directors to resolve on new issue of ordinary shares and warrants and/or convertibles

Yes No